GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ERα glycosylation and stability to cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33731348.
- Also identified by DOI 10.1126/sciadv.abe2470 and PMC identifier 7968844.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
What covalent modifications control the temporal ubiquitination of ERα and hence the duration of its transcriptional activity remain poorly understood. We show that GREB1, an ERα-inducible enzyme, catalyzes O-GlcNAcylation of ERα at residues T553/S554, which stabilizes ERα protein by inhibiting association with the ubiquitin ligase ZNF598. Loss of GREB1-mediated glycosylation of ERα results in reduced cellular ERα levels and insensitivity to estrogen. Higher <i>GREB1</i> expression in ERα<sup>+ve</sup> breast cancer is associated with greater survival in response to tamoxifen, an ERα agonist. Mice lacking <i>Greb1</i> exhibit growth and fertility defects reminiscent of phenotypes in ERα-null mice. In summary, this study identifies GREB1, a protein with an evolutionarily conserved domain related to DNA-modifying glycosyltransferases of bacteriophages and kinetoplastids, as the first inducible and the only other (apart from OGT) O-GlcNAc glycosyltransferase in mammalian cytoplasm and ERα as its first substrate.
Medical subject headings
- Breast Neoplasms
- Estrogen Receptor alpha
- Membrane Proteins